Citation: M. Zwitter et al., Gemcitabine and vincristine: an effective outpatient regimen with low myelotoxicity for stage IV non-small cell lung cancer, NEOPLASMA, 48(3), 2001, pp. 200-202
Authors:
Brodowicz, T
Kostler, WJ
Moslinger, R
Tomek, S
Vaclavik, I
Herscovici, V
Wiltschke, C
Steger, GG
Wein, W
Seifert, M
Kubista, E
Zielinski, CC
Citation: T. Brodowicz et al., Single-agent gemcitabine as second- and third-line treatment in metastaticbreast cancer, BREAST, 9(6), 2000, pp. 338-342
Authors:
Krajnik, G
Mohn-Staudner, A
Thaler, J
Greil, R
Schmeikal, S
Marhold, F
Deutsch, J
Preiss, P
Malayeri, R
Schafer-Prokop, C
Wein, W
Huber, H
Pirker, R
Citation: G. Krajnik et al., Vinorelbine-gemcitabine in advanced non-small-cell lung cancer (NSCLC): AnAASLC phase II trial, ANN ONCOL, 11(8), 2000, pp. 993-998
Authors:
Winkler, H
Janata, O
Berger, C
Wein, W
Georgopoulos, A
Citation: H. Winkler et al., In vitro release of vancomycin and tobramycin from impregnated human and bovine bone grafts, J ANTIMICRO, 46(3), 2000, pp. 423-428
Authors:
Krajnik, G
Wein, W
Greil, R
Marhold, F
Mohn-Staudner, A
Kummer, F
Malayeri, R
Zochbauer-Muller, S
Huber, H
Pirker, R
Citation: G. Krajnik et al., Vinorelbine/gemcitabine in advanced non-small cell lung cancer (NSCLC): a phase I trial, EUR J CANC, 34(12), 1998, pp. 1977-1980